Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors.

ABSTRACT: Advancement in sequencing technologies allows for the identification of molecular pathways involved in tumor progression and treatment resistance. Implementation of novel agents targeting these pathways, defined as targeted therapy, significantly improves the prognosis of cancer patients. Targeted therapy also includes the use of monoclonal antibodies (mAbs). These drugs recognize specific oncogenic proteins expressed in cancer cells. However, as with many other types of targeting agents, mAb-based therapy usually fails in the long-term control of cancer progression due to the development of resistance. In many cases, resistance is caused by the activation of alternative pathways involved in cancer progression and the development of immune evasion mechanisms. To overcome this off-target re

SUBMITTER: Liguori L 

PROVIDER: S-EPMC9694302 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature